Dementia and Alzheimer Disease

The Gary Sinise Foundation Avalon Network aims to combat TBI and post-traumatic stress in veterans and first responders.

Researchers studied associations between CSF neurofilament light, neurogranin, and t-tau with measures of cortical thickness, white matter hyperintensities, and microstructural integrity.

Alzheimer disease-related neurodegeneration was correlated only with the thickness of the ganglion cell-inner plexiform layer.

There were no significant treatment group differences for measures of Alzheimer disease regional atrophy, cerebral blood flow, or mean fractional anisotropy.

The FDA cited a lack of statistical significance in some of the subgroups of dementia, and insufficient numbers of patients with certain less common dementia subtypes as lack of substantial evidence of effectiveness to support approval.

Here's what is coming soon to NeurologyLive.

Researchers found improvements in SIB and NPI score between high-dose and placebo groups.

Researchers on the FDA’s advisory committee conducted a review of the studies and evidence ahead of the treatment’s PDUFA date on June 7, 2021.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 2, 2021.

A recently completed phase 1 program found that ITI-1284 ODT-SL was rapidly absorbed into the systemic circulation, was metabolically stable, and resulted in high systemic exposure.

Compared to participants who never experienced a head injury, a history of a single prior head injury was associated with a 1.25 times increased risk of dementia.

The director of the Lou Ruvo Center for Brain Health and neurologist at Cleveland Clinic discussed whether lenalidomide, a repurposed cancer drug, has promise as an Alzheimer disease DMT.

The director of the Institute for Health, Health Care Policy, and Aging Research at Rutgers University discussed the reasons behind the lack of real-world dementia studies.

Here's what is coming soon to NeurologyLive.

Howard Fillit, MD, the founding executive director and chief science officer, Alzheimer's Drug Discovery Foundation, shared his thoughts on the recently published data.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending March 26, 2021.

AC Immune SA is also developing an optimized formulation being tested in mice and non-human primates.

The director of the Institute for Health, Health Care Policy, and Aging Research at Rutgers University discussed how patient feedback can positively impact the direction of dementia research.

With the FDA is set to decide on the possible approval of aducanumab in June, the remaining pipeline for Alzheimer therapies is loaded with potential for the future.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending March 19, 2021.

The director of the Institute for Health, Health Care Policy, and Aging Research at Rutgers University discussed his recent findings on assessing evidence for dementia care interventions.

Despite showing better composite scores for cognition and ability to perform activities of daily living, a number of the secondary outcomes showed mixed results with the Eli Lilly investigational agent.

Here's what is coming soon to NeurologyLive.

Students share their experience in the virtual classroom, navigating new requirements, and the lessons learned from their position in a global pandemic.

Patients treated with the GammaSense neuromodulation therapeutic also demonstrated a significant 61% reduction in whole brain atrophy and volumetric loss associated with Alzheimer disease.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending March 12, 2021.

The chief diversity, equity and inclusion officer at the Alzheimer’s Association discussed the findings of the association’s special edition of its annual Facts and Figures report.

The director of the Lou Ruvo Center for Brain Health and neurologist at Cleveland Clinic discussed the research opportunities for repurposed anti-inflammatory drugs for Alzheimer disease.

Treatment with masitinib was shown to prevent the amyloid-induced hemichannel-dependent mast cell activity in bone marrow-derived mast cells and brain mast cells.